HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Speaker at Global Conference on Pharmaceutics and Drug Delivery Systems 2018 - Vandana B. Patravale
Institute of Chemical Technology, India
Title : Brain targeted nanotherapeutics: An enticing journey from ideation to product realization Vandana B Patravale


Dementia (neurodegenerative ailments) accounts for over 50 million cases worldwide with estimated new 7.7 million cases every year. Neurodegenerative ailments associated progressive decline in clinical condition mainly results from poor transport of therapeutic actives across blood brain barrier (BBB) and oxidative stress induced disease progression. To overcome this challenge, we developed smart targeted micellar nanocarriers (t-micelles) comprising a novel lipid bioconjugate (t-ligand) with an inherent ability to circumvent BBB via active transport pathway (patented technology). The t-ligand was designed using in silico glide molecular docking on BBB active transport receptor crystal structure. Designed t-ligand exhibited selective affinity binding at the BBB active transport receptor site and was synthesized successfully. The t-ligand exhibited self-assembling property and the resulting micellar geometry was optimized using SANS tool.
       For therapeutic application, t-micelles of donepezil (first line drug for treatment of dementia) were developed and incorporated in gel for microneedle assisted transdermal delivery. t-Micelles showed 1.6 fold higher brain permeation in zebra fish model as competed to plain micelles. The Draize patch test confirmed suitability of proposed treatment regimen and showed 4 fold increment in skin permeability flux as compared to treatment without microneedle patch.  In vivo pharmacokinetic and biodistribution studies demonstrated 3 fold rise in bioavailability with significantly high donepezil brain uptake when given as microneedle pretreated transdermal t-micellar gel in contrast to marketed oral formulation. As second application, t-micelles of curcumin (antioxidant-neuroprotective drug for treatment of neurodegenerative disorders) were also developed and incorporated into a nasal spray for nose-to-brain delivery. In vivo pharmacokinetic and biodistribution studies demonstrated enhanced brain transport of curcumin with t-micelles mainly in the dementia sensitive areas of brain viz. olfactory region, hippocampus and cerebellum. The studies confirmed the potential of t-micelles as a platform Trojan Horse strategy to improve the brain delivery of therapeutic actives and confirmed its suitability towards effective delivery via multiple routes of administration.
Audience take away:
• A scientific and rationale thought process for innovative targeted nanoformulation development
• Step by step approach towards in-depth planning and execution from ideation to product realization
Key features:
• Next generation novel, targeted and efficacious strategy to treat neurological ailments
• Industrially feasible and scalable platform technology
• Patented technology


Vandana Patravale is Professor of Pharmaceutics at Department of Pharmaceutical Sciences and Technology of Institute of Chemical Technology, India. She has over 100 refereed publications, 8 granted patents, 24 patents in pipeline, 2 trademark registries with over 250 research presentations and 50 invited lectures at major national and international scientific meetings. She has published two books entitled, ‘Nanotechnology in drug delivery-A Perspective on transition from laboratory to market’ and ‘Pharmaceutical product development: insights into pharmaceutical processes, management and regulatory affairs’. She is recipient of prestigious Bill and Melinda Gates Foundation grant to develop the first ever eco-friendly nanovaccine for nasal immunization and was bestowed with esteemed awards like OPPI women scientist award 2015, Best Pharmaceutical Scientist award 2014, VASVIK award 2013, Veneto nanotech award 2013, APTI best teacher award 2012.